PAPPA Antibody

1. Serum PAPP-A at third trimester of pregnancy was not associated with late-onset pre-eclampsia and intrauterine growth retardation after 34weeks of pregnancy. PMID: 29674192
2. Elevated PROK1 in the first pregnancy trimester is a more effective marker than PAPP-A in the prediction of pre-eclampsia and fetal growth restriction. PMID: 28675948
3. The findings suggest a possible pathophysiological link between the development of Fetal growth restriction and the expression of PAPPA, PAPPA2 and PLAC-1. PMID: 29532882
4. Data suggest that PGF and PAPPA serve as serum biomarkers for early diagnosis of gestational hypertension. These studies were conducted at antenatal clinics in Ghana using blood from women between 8 and 13 weeks gestation. (PGF = placental growth factor; PAPPA = pregnancy-associated plasma protein-A) PMID: 29587776
5. Pregnancy associated plasma protein-A (PAPP-A) appears to be a potentially useful biomarker for short-term risk stratification of patients presenting with chest pain of ischemic origin (Review). PMID: 29144175
6. These data suggested that hsa_circ_0004904 and hsa_circ_0001855 combined with PAPP-A might be promising biomarkers for the detection of Preeclampsia. Bioinformatics analysis predicted that hsa_circ_0004904 and hsa_circ_0001855 miRNA sponges directly target PAPP-A. PMID: 29758559
7. higher first trimester serum values seem to be associated with placenta accreta in women with placenta previa PMID: 28027672
8. Studied the role of pregnancy-associated plasma protein A (PAPP-A) in the outcome of ischemic cerebrovascular disease. PMID: 27809366
9. maternal serum levels associated with small for gestational age neonates, preterm birth, and pre-eclampsia PMID: 28514830
10. PAPP-A and ProMBP are associated with increased risk of death in heart failure patients. PMID: 28537443
11. low levels not associated with high serum estradiol at controlled ovarian stimulation PMID: 28606451
12. PAPP-A C/C genotypes were more frequent among mothers with gestational diabetes than in control. PMID: 28655969
13. Elevated PAPP-A compared to other risk factors was a stronger predictor for future CV events 2 years post ACS in patients with type 2 diabetes mellitus. PMID: 28381225
14. PAPP-A, like CCS and CIMT, is a parameter that can be used to detect subclinical atherosclerosis. PMID: 28791822
15. Results suggest that links between PAPP-A concentrations in early pregnancy and subsequent glucose concentrations and blood pressures may be mediated by changes in insulin sensitivity (and secretion). PMID: 28323969
16. Collectively, these results identify PAPP-A as a pregnancy-dependent oncogene while also showing that extended lactation is protective against PAPP-A-mediated carcinogenesis. PMID: 26951623
17. Lower PlGF and higher PAPP-A and free beta-hCG levels were found in the fetal circulation of near-term severe preeclamptic pregnancies PMID: 27809614
18. PAPP-A 1224 SNP has a significant effect on the level and activity of PAPP-A in human follicles, suggesting that the follicular fluid level of bioactive insulin-like growth factor depends on the genotype. PMID: 27793387
19. This study demonstrated no association between PAPP-A gene rs7020782 polymorphism and Preeclampsia (PE) and intrauterine growth restriction. PMID: 26520690
20. data indicate that PAPP-A promotes TF expression in human endothelial cells and support the hypothesis that this proteinase, besides being involved in progression of atherosclerosis, does not represent an independent risk factor for adverse cardiovascular events, but it rather might play an "active" role in the pathophysiology of ACS as an effector molecule able to induce a pro-thrombotic phenotype in endothelial cells PMID: 27007282
21. assessed serum PAPP-A levels in COPD and the associations with disease severity; elevated levels of PAPP-A were observed in patients with COPD PMID: 27090654
22. STC2 is involved in regulating PAPP-A activity during the development of atherosclerosis PMID: 26983002
23. Data suggest that stanniocalcin 1 and 2 (STC1, STC2) participate in inhibition of proteolytic activity of pregnancy-associated plasma protein-A (PAPP-A) during folliculogenesis. PMID: 26874357
24. measurements of maternal serum PAPP-A concentration in the first trimester predict severe fetal growth restriction more effectively than they predict a birth weight below the 10th percentile among a Chinese population PMID: 25845987
25. Women with PAPP-A /=90th percentile is protective against small for gestational age, and is associated with an increased risk of large for gestational age for infants born after 32 weeks gestation. PMID: 26773241
26. Data suggest that incidences of intrauterine growth restriction, pre-eclampsia, preterm birth, and fetal death are significantly greater in pregnant women with low serum levels of PAPP-A in first trimester (9-13 weeks of pregnancy) as compared to control pregnant women; study was conducted in India. PMID: 25773764
27. The first trimester maternal PAPP-A levels were decreased in the ICSI group compared with those in the controls, but not in IVF and embryo transfer groups. PMID: 26697810
28. miR-141 may play important roles in ox-LDL-induced abnormal proliferation of the vascular smooth muscle cells by targeting PAPPA. PMID: 26823756
29. Combined analysis of PAPP-A and free beta-hCG appears to be a potential candidate to predict early fetal loss. PMID: 25159705
30. PAPP-A in ascites and tissue-associated PAPP-A serve to increase IGF bioactivity and, thereby, to stimulate IGF-IR-mediated ovarian tumor growth. PMID: 26336825
31. PAPP-A determination during the first trimester of pregnancy in women at risk for IUGR makes possible the prophylactic treatment and monitoring of pregnancy. PMID: 27125092
32. Data indicate that rising pregnancy-associated plasma protein-A (PAPP-A) levels are prognostic in patients with coronary artery disease (CAD). PMID: 26223809
33. PAPP-A serum concentrations differed significantly between Asian and European women during the first trimester of pregnancy. PMID: 25858516
34. The study findings showed that plasma sCD40L, fetuin-A, and PAPP-A levels are associated with carotid plaque formation and instability. PMID: 26214492
35. For Down syndrome affected pregnancies, the median MoM of first trimester PAPP-A, PlGF, and AFP were significantly reduced, and free-beta-hCG were significantly elevated. PMID: 25846403
36. Increased PAPP-A in the first trimester is associated with placenta accreta. PMID: 24226752
37. Maternal serum PAPP-A was not associated with fetal open spina bifida. PMID: 24226839
38. The A>C variation of rs7020782 of PAPPA might be an independent risk factor for carotid plaque development and calcification. PMID: 26122709
39. Elevated PAPP-A was associated with fetal macrosomia. PMID: 24155168
40. Suggest that PAPP-A is specifically involved in the regulation of steroidogenesis in human antral follicles. PMID: 26297643
41. The performance of screening for GDM by maternal factors was not improved by the addition of PAPP-A and/or PLGF. First trimester maternal serum PAPP-A and PLGF are not useful in screening for GDM. PMID: 26362726
42. serum variations during the first trimester cannot be used as a marker of excessive fetal growth PMID: 24940710
43. Data suggest both serum PAPP-A and serum CRP (high-sensitivity C-reactive protein) are up-regulated during first trimester in women who will undergo early pregnancy failure. PMID: 25596909
44. PAPPA was similar between pregnant women with chronic kidney disease and controls. PMID: 25395363
45. Median PAPP-A MoM was 1.01 in the control group and 1.05 (P = 0.83) in praevia, compared with 1.22 in abnormally invasive placentation cases (0.16). PMID: 25639820
46. A PAPP-A value, expressed in MoM, of 1.25 is a predictive factor of fetal birth weight >4000 g PMID: 24743523
47. first trimester PAPP-A levels were measured to see if they were associated with negative pregnancy outcome. Groups with high and low PAPP-A significantly differed only in miscarriages. PMID: 25139218
48. inadequate sensitivity as first trimester serum marker for pre-eclampsia PMID: 24786703
49. Serum PAPP-A levels were closely associated with the coronary no-reflow phenomenon during percutaneous coronary intervention. PMID: 24227626
50. High PAPP-A expression is associated with breast cancer. PMID: 25468445

显示更多

收起更多

HGNC: 8602

OMIM: 176385

KEGG: hsa:5069

STRING: 9606.ENSP00000330658

UniGene: Hs.643599